Ali Alhadab

577 total citations
11 papers, 195 citations indexed

About

Ali Alhadab is a scholar working on Oncology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Ali Alhadab has authored 11 papers receiving a total of 195 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Epidemiology and 3 papers in Infectious Diseases. Recurrent topics in Ali Alhadab's work include Pharmacogenetics and Drug Metabolism (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Antifungal resistance and susceptibility (2 papers). Ali Alhadab is often cited by papers focused on Pharmacogenetics and Drug Metabolism (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Antifungal resistance and susceptibility (2 papers). Ali Alhadab collaborates with scholars based in United States, United Kingdom and South Korea. Ali Alhadab's co-authors include Richard C. Brundage, Bożena M Morawski, Darlisha A Williams, SRUTI S VELAMAKANNI, Abdu K Musubire, Andrew Akampurira, Kirsten Nielsen, Mahsa Abassi, Reuben Kiggundu and Lillian Tugume and has published in prestigious journals such as Journal of Clinical Oncology, Antimicrobial Agents and Chemotherapy and The Lancet Infectious Diseases.

In The Last Decade

Ali Alhadab

11 papers receiving 193 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ali Alhadab United States	6	114	112	29	29	24	11	195
Minh-Vu H Nguyen United States	10	150 1.3×	185 1.7×	23 0.8×	21 0.7×	15 0.6×	23	253
Shireen Khan United States	5	87 0.8×	103 0.9×	17 0.6×	74 2.6×	104 4.3×	8	276
A Bucko United States	11	176 1.5×	65 0.6×	25 0.9×	34 1.2×	11 0.5×	17	426
Ya-Ling Huang Taiwan	7	62 0.5×	76 0.7×	33 1.1×	32 1.1×	88 3.7×	9	243
Sashen Moodley South Africa	5	164 1.4×	196 1.8×	12 0.4×	14 0.5×	52 2.2×	8	241
Gary A. Harding Canada	8	95 0.8×	109 1.0×	46 1.6×	56 1.9×	122 5.1×	10	332
Fengyao Wu China	8	140 1.2×	133 1.2×	6 0.2×	31 1.1×	46 1.9×	13	273
Victoria Dulière France	6	75 0.7×	212 1.9×	19 0.7×	17 0.6×	42 1.8×	8	301
Qiaoyang Lu United States	8	201 1.8×	241 2.2×	49 1.7×	19 0.7×	52 2.2×	15	346

Countries citing papers authored by Ali Alhadab

Since Specialization

Citations

This map shows the geographic impact of Ali Alhadab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Alhadab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Alhadab more than expected).

Fields of papers citing papers by Ali Alhadab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Alhadab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Alhadab. The network helps show where Ali Alhadab may publish in the future.

Co-authorship network of co-authors of Ali Alhadab

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Alhadab. A scholar is included among the top collaborators of Ali Alhadab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Alhadab. Ali Alhadab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Leighl, Natasha B., Hiroaki Akamatsu, Ying Cheng, et al.. (2024). Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA8505–LBA8505. 12 indexed citations

Lim, Sun Min, Josiane Mourão Dias, Pei Jye Voon, et al.. (2024). Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.. Journal of Clinical Oncology. 42(17_suppl). LBA8612–LBA8612. 3 indexed citations

Alhadab, Ali, et al.. (2023). Case–control matching‐guided exposure‐efficacy relationship for avelumab in patients with urothelial carcinoma. CPT Pharmacometrics & Systems Pharmacology. 12(12). 2001–2012. 3 indexed citations

Minchom, Anna, Matthew Krebs, Byoung Chul Cho, et al.. (2023). Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.. Journal of Clinical Oncology. 41(16_suppl). 9126–9126. 7 indexed citations

Yang, Derek Z., Ali Alhadab, Kourosh Parivar, Diane D. Wang, & Mohamed Elmeliegy. (2021). Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations. Clinical Pharmacology & Therapeutics. 112(4). 782–790. 4 indexed citations

Alhadab, Ali & Richard C. Brundage. (2020). Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysis. The AAPS Journal. 22(4). 73–73. 13 indexed citations

Alhadab, Ali & Richard C. Brundage. (2020). Physiologically‐Based Pharmacokinetic Model of Sertraline in Human to Predict Clinical Relevance of Concentrations at Target Tissues. Clinical Pharmacology & Therapeutics. 108(1). 136–144. 4 indexed citations

Alhadab, Ali, Ahmed Hamed Salem, & Kevin J. Freise. (2020). Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. Clinical and Translational Science. 13(3). 555–562. 7 indexed citations

Alhadab, Ali, Joshua Rhein, Lillian Tugume, et al.. (2019). Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis. Journal of Pharmacokinetics and Pharmacodynamics. 46(6). 565–576. 4 indexed citations

10.

Alhadab, Ali, et al.. (2018). Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients. Antimicrobial Agents and Chemotherapy. 62(4). 15 indexed citations

11.

Rhein, Joshua, Bożena M Morawski, Kathy Huppler Hullsiek, et al.. (2016). Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. The Lancet Infectious Diseases. 16(7). 809–818. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact